# Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Study · id `cardio:ct-nct01320202` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01320202](<https://clinicaltrials.gov/study/NCT01320202>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01320202

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.

## Technical summary

Registry record NCT01320202. Randomized; single masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2015-04-28.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 305 participants (enrolled count; ClinicalTrials.gov record NCT01320202, source copy `cardio:ctgov-nct01320202-2017-04-26`, retrieved 2026-10-26)
- Start date: 2011-03 (registry gives no type) (ClinicalTrials.gov record NCT01320202, source copy `cardio:ctgov-nct01320202-2017-04-26`, retrieved 2026-10-26)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01320202, source copy `cardio:ctgov-nct01320202-2017-04-26`, retrieved 2026-10-26)
- Completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01320202, source copy `cardio:ctgov-nct01320202-2017-04-26`, retrieved 2026-10-26)
- Results first posted: 2015-04-28 (ClinicalTrials.gov record NCT01320202, source copy `cardio:ctgov-nct01320202-2017-04-26`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT01320202, source copy `cardio:ctgov-nct01320202-2017-04-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01320202-2017-04-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
- Acronym: CRUISE 1
- Condition: Renal Failure Chronic Requiring Hemodialysis
- Intervention (Drug): Soluble Ferric Pyrophosphate (SFP)
- Intervention (Device): Standard dialysate
- Lead sponsor: Rockwell Medical Technologies, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Rockwell Medical Technologies, Inc. (`cardio:org-rockwell-medical-technologies-inc`)

## Provenance

Content hash: 12728f9027cc83d620ab3f0e4b6b512dbb45e8dbfda5497df50f4750ed9a2148
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
